Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022

Update: 2023-01-24

Description

In our first podcast episode of 2023, Back Bay’s strategic advisors summarize some of the most compelling healthcare development stories from 2022. From CRISPR and gene editing advancement to cross-species organ transplantation and the latest in the evolving regulatory and reimbursement landscape, these stories captivated us and continue to herald progress in health and human care.

Podcast experts include Brendan Wang, Christian Thienel and Peter Bak, with special thanks to Micheka Fenelon.

Comments

In Channel

A Capital Markets Outlook for 2025: 2024, A Year in Review

2025-02-0715:58

The Optimism of Bispecific Antibodies

2024-11-0826:39

Dynamics in Healthcare Focused Markets

2024-09-3020:49

From NASH to MASH: Current Market Dynamics in Hepatology

2024-09-1628:19

Key Considerations for a US Healthcare IPO

2024-05-2235:03

Drug Development in Obesity

2024-04-3026:56

The Current Dynamics in Capital Markets

2024-04-1522:25

Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments

2024-03-1837:34

Trends and Investment Activity in Radiopharmaceuticals and Psychedelics

2024-02-1425:52

Vertex’s Exa-cel to Biogen and Sage’s Zurzuvae: Notable Product Approvals of 2023

2024-01-0325:26

Monthly Roundup of News from Healthcare Development

2023-11-0730:04

The Current and Future Landscape of Healthcare IPO Markets

2023-10-2723:41

The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease

2023-10-1224:43

The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates

2023-08-2925:54

Investing in Health Tech & Digital Medicine: Expert Talk with Mikaela Odlander & Edward Kliphuis

2023-04-1429:03

Contingencies for Biopharma, Medtech Deal Planning in a Down Market

2023-02-0928:35

Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022

2023-01-2437:16

Preparing BioPharma and Medtech Companies for Public Listing - Back Bay Life Science Advisors and Nasdaq Nordic

2022-09-1928:01

The Promising Field of Targeted Protein Degraders (TPDs)

2022-07-3023:10

Early Market Access and Pricing with Pete Bak, Christian Thieniel and Brendan Wang

2022-07-0629:44

00:00

1.0x

Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022

Jonathan P. Gertler and Peter Bak

#box-pro-ellipsis-176281277302519{-webkit-line-clamp:2;}Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022

Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022

Jonathan P. Gertler and Peter Bak

Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022